Cantargia: Closing in on a Licensing Deal? - Redeye
Redeye updates its view on Cantargia following a period that has brought promising trial results and the initiation of several new clinical projects. We adjust our estimates and valuation based on new timelines and an updated WACC.
ANNONS
Redeye updates its view on Cantargia following a period that has brought promising trial results and the initiation of several new clinical projects. We adjust our estimates and valuation based on new timelines and an updated WACC.